Filing Flows › TG Therapeutics (TGTX) › Q1 2025
TG Therapeutics (TGTX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
TG Therapeutics (TGTX) reported revenue of $121M for the first quarter 2025 (Q1 2025), +90% from a year earlier and +12% from the quarter before. Operating margin was 7.1%, net earnings $5.1M (4.2% of revenue).
TG Therapeutics, Q1 2025: revenue $121M (+90% year over year), operating margin 7.1%, net earnings $5.1M, operating cash flow −$28.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121M | +12% | +90% |
| Operating profit | $8.6M | -71% | — |
| Net earnings | $5.1M | -78% | — |
| Operating cash flow | −$28.7M | — | — |
What changed
Revenue was $120.9M in Q1 2025, up 90% year over year and up 12% from the previous quarter. Product was the largest line at 99% of revenue. Product added $69.2M year over year (up 137%), 121% of the total change.
Operating profit was $8.6M, a 7.1% margin (up 21.7 points year over year). Total costs grew 54% against revenue growth of 90%. The fastest-growing cost line was Cost of revenue (+186%). Net earnings were $5.1M. The effective tax rate was 7.5%.
Operating cash flow was −$28.7M. Non-cash charges added back $8K of depreciation and amortization and $15.0M of share-based compensation. Working capital and other items used $48.8M. Capital expenditures of $25K exceeded it, leaving free cash flow of −$28.7M.
Questions
What was TG Therapeutics' revenue in the first quarter 2025?
TG Therapeutics (TGTX) reported revenue of $121M for the first quarter 2025 (Q1 2025), +90% from a year earlier and +12% from the quarter before.
Was TG Therapeutics profitable in the first quarter 2025?
Operating profit was $8.6M (7.1% of revenue) and net earnings $5.1M.
Source: TG Therapeutics 10-Q on SEC EDGAR.